P Vestergaard1, L Rejnmark, L Mosekilde. 1. Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus Sygehus, Tage Hansens Gade 2, 8000, Aarhus C, Denmark. p-vest@post4.tele.dk
Abstract
INTRODUCTION: Our objective was to study the association between fracture risk and the use of anxiolytics and sedatives (benzodiazepines, etc.), neuroleptics and antidepressants. SUBJECTS AND METHODS: This was a case control study. All cases consisted of subjects who had sustained a fracture during the year 2000 (n=124,655). For each case, three controls (n=373,962) matched for age and gender were randomly drawn from the background population. Exposure was defined as the use of neuroleptics, antidepressants and anxiolytics/sedatives, psychiatric disease (manic depressive states, schizophrenia, other psychoses), and other confounders. The effect of dose was examined as a defined daily dose per day (DDD/day). The values referred to are confounder-adjusted. RESULTS: For anxiolytics and sedatives, there was a small increase in overall fracture risk (OR: around 1.1) even with limited doses (<0.1 DDD/day). No dose-response relationship was observed for anxiolytics and sedatives. For neuroleptics, a limited increase in overall fracture risk was observed (OR: around 1.2 from <0.05 DDD/day with no dose-response relationship). For antidepressants, a dose-response relationship was observed for fracture risk (OR: increasing from 1.15, 95% CI: 1.11-1.19 at <0.15 DDD/day to 1.40, 95% CI: 1.35-1.46 for >or=0.75 DDD/day). The risk of fracture was higher with selective serotonin re-uptake inhibitors than with tricyclic antidepressants. CONCLUSIONS: Small increases in fracture risk were seen with the use of anxiolytics and sedatives and neuroleptics without a dose-response relationship. The increase may be linked to an increased risk of falls. For antidepressants, a dose-response relationship was found, with a higher fracture risk for selective serotonin re-uptake inhibitors.
INTRODUCTION: Our objective was to study the association between fracture risk and the use of anxiolytics and sedatives (benzodiazepines, etc.), neuroleptics and antidepressants. SUBJECTS AND METHODS: This was a case control study. All cases consisted of subjects who had sustained a fracture during the year 2000 (n=124,655). For each case, three controls (n=373,962) matched for age and gender were randomly drawn from the background population. Exposure was defined as the use of neuroleptics, antidepressants and anxiolytics/sedatives, psychiatric disease (manic depressive states, schizophrenia, other psychoses), and other confounders. The effect of dose was examined as a defined daily dose per day (DDD/day). The values referred to are confounder-adjusted. RESULTS: For anxiolytics and sedatives, there was a small increase in overall fracture risk (OR: around 1.1) even with limited doses (<0.1 DDD/day). No dose-response relationship was observed for anxiolytics and sedatives. For neuroleptics, a limited increase in overall fracture risk was observed (OR: around 1.2 from <0.05 DDD/day with no dose-response relationship). For antidepressants, a dose-response relationship was observed for fracture risk (OR: increasing from 1.15, 95% CI: 1.11-1.19 at <0.15 DDD/day to 1.40, 95% CI: 1.35-1.46 for >or=0.75 DDD/day). The risk of fracture was higher with selective serotonin re-uptake inhibitors than with tricyclic antidepressants. CONCLUSIONS: Small increases in fracture risk were seen with the use of anxiolytics and sedatives and neuroleptics without a dose-response relationship. The increase may be linked to an increased risk of falls. For antidepressants, a dose-response relationship was found, with a higher fracture risk for selective serotonin re-uptake inhibitors.
Authors: Stuart J Warden; Alexander G Robling; Megan S Sanders; Michael M Bliziotes; Charles H Turner Journal: Endocrinology Date: 2004-11-11 Impact factor: 4.736
Authors: Samuel Y S Wong; Edith M C Lau; Henry Lynn; P C Leung; Jean Woo; Steve R Cummings; Eric Orwoll Journal: Osteoporos Int Date: 2004-09-23 Impact factor: 4.507
Authors: C Moura; S Bernatsky; M Abrahamowicz; A Papaioannou; L Bessette; J Adachi; D Goltzman; J Prior; N Kreiger; T Towheed; W D Leslie; S Kaiser; G Ioannidis; L Pickard; L-A Fraser; E Rahme Journal: Osteoporos Int Date: 2014-02-25 Impact factor: 4.507
Authors: J C Munson; J P W Bynum; J-E Bell; C McDonough; Q Wang; T Tosteson; A N A Tosteson Journal: Osteoporos Int Date: 2018-09-19 Impact factor: 4.507
Authors: Leslie Spangler; Delia Scholes; Robert L Brunner; John Robbins; Susan D Reed; Katherine M Newton; Jennifer L Melville; Andrea Z Lacroix Journal: J Gen Intern Med Date: 2008-02-20 Impact factor: 5.128